Evotec SE stock (DE0005664809): Q1 2026 loss and weak margins keep valuation in focus

Evotec SE shares traded slightly higher on Xetra at EUR 5.14 on 06/05/2026 despite the biotech group reporting a revenue decline and negative EBITDA margin for Q1 2026, keeping investors focused on profitability and valuation metrics.

Evotec SE shares showed a modest gain in Germany on 06/05/2026, with the stock changing hands at 5.14 EUR on Xetra around midday, up about 0.4–0.5% compared with the previous close, according to finanzen.net and other exchange data as of that date.finanzen.net as of 06/05/2026

The Hamburg-based biotechnology group, whose primary listing is in Germany, is still digesting a weak start to the year after reporting a double-digit revenue decline and negative profitability for Q1 2026, which frames the discussion around its current valuation levels.Investing.com company news as of 05/21/2026

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Biotechnology / drug discovery and development services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe, United States, Asia-Pacific
• Key revenue drivers: Discovery alliances, development partnerships, and milestone/royalty agreements with pharmaceutical and biotech companies
• Home exchange/listing venue: Xetra (EVT)
• Trading currency: EUR

Evotec SE: core business model

Evotec SE operates as a contract research and development partner for the pharmaceutical and biotechnology industry, generating revenue primarily from discovery and development services alongside milestones and potential royalties on partnered drug candidates.

Valuation metrics and multiples for Evotec SE

The weak start to 2026 has sharpened the market focus on Evotec SE's valuation metrics, especially given that the company is currently loss-making on an EBITDA basis while continuing to invest heavily in its partnered pipeline and platform capabilities. According to an earnings summary covering the latest reported quarter, Evotec SE generated Q1 2026 revenues of approximately 156.6 million EUR, representing a decline of around 21.7–22% year-on-year and signaling that near-term growth has stalled as the group executes its transformation program.Investing.com earnings transcript as of 05/21/2026

In the same Q1 2026 period, Evotec SE's adjusted group EBITDA swung to a loss of about 21.9 million EUR compared with a positive 3.1 million EUR in Q1 2025, and the gross margin turned negative at roughly -1.6% versus a positive 33.3% a year earlier, according to the same Q1 2026 coverage published on 05/21/2026.Investing.com company news as of 05/21/2026 These figures imply that traditional profit-based valuation multiples such as price-to-earnings or EV/EBITDA are currently less meaningful, shifting attention instead to revenue-based measures, the scale of the company's partnership pipeline, and the potential for future milestone and royalty streams.

On the US market, Evotec SE's American depositary shares traded on Nasdaq under the ticker EVO recently closed around USD 2.96–2.97 with a market capitalization reported at roughly USD 1.06 billion and a consensus price target of about USD 7.00, according to MarketBeat data for the session ending 06/04/2026.MarketBeat as of 06/04/2026 With no dividend currently indicated and negative earnings, investors looking at valuation appear to be weighing the discount implied by the current share price versus the risks associated with achieving a sustainable return to profitability after the sharp margin compression seen in Q1 2026.

Conclusion

With Evotec SE shares edging slightly higher on Xetra at 5.14 EUR on 06/05/2026, the market reaction to the company's weak Q1 2026 figures has so far been muted, even though revenues fell by roughly 22% year-on-year and EBITDA turned negative for the quarter. The latest valuation context, including negative margins and a market capitalization of about USD 1.06 billion against a consensus price target above the current US trading level, shows that investors are carefully balancing the risks of sustained losses against the potential long-term payoff from Evotec SE's discovery and development partnerships.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.